HUTCHMED (HCM) lung cancer combo tops China Phase III trial

Q: What did HUTCHMED (HCM) announce about the SANOVO Phase III trial?

HUTCHMED announced that the China Phase III SANOVO trial in treatment-naïve EGFR-mutated, MET-overexpressing NSCLC showed a statistically significant and highly clinically meaningful improvement in progression-free survival for ORPATHYS® plus TAGRISSO® versus TAGRISSO® alone, with encouraging overall survival data and no new safety findings.

Q: What were the primary and key secondary endpoints in HCM’s SANOVO study?

The primary endpoint of SANOVO was progression-free survival (PFS) assessed by investigators. Other endpoints include PFS by independent review, overall survival (OS), objective response rate, duration of response, disease control rate, time to response, and safety, all in treatment-naïve EGFR-mutated, MET-overexpressing NSCLC.

Q: How many patients were enrolled in HUTCHMED’s (HCM) SANOVO trial and how were they treated?

SANOVO randomized 326 treatment-naïve patients in a 1:1 ratio to receive TAGRISSO® 80 mg once daily plus either ORPATHYS® or placebo at 300/200 mg twice daily, with ORPATHYS® dosing based on body weight, to compare the combination against TAGRISSO® alone.

Q: What is the current approval status of ORPATHYS® in China mentioned by HCM?

ORPATHYS® is approved in China for MET exon 14 skipping NSCLC and conditionally approved for MET-amplified gastric or gastroesophageal junction cancer after at least two prior systemic treatments. In combination with TAGRISSO®, it is approved for EGFR mutation-positive NSCLC with MET amplification after EGFR TKI progression.

Q: How common is EGFR-mutated NSCLC according to HUTCHMED’s (HCM) disclosure?

HUTCHMED cites sources indicating that 10–15% of NSCLC patients in the US and Europe, and 30–40% of patients in Asia, have EGFR-mutated NSCLC. Lung cancer accounts for about 23% of global cancer deaths, and 80–85% of lung cancers are NSCLC.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

HUTCHMED (China) Ltd (HCM) reports positive top-line results from the China Phase III SANOVO trial in treatment-naïve patients with locally advanced or metastatic EGFR-mutated, MET-overexpressing NSCLC. ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) showed a statistically significant and highly clinically meaningful improvement in progression-free survival versus TAGRISSO® alone in both high-MET and intention-to-treat populations.

The combination also showed a very encouraging overall survival benefit as a secondary endpoint, with safety consistent with known profiles and no new safety findings. SANOVO randomized 326 patients 1:1 to TAGRISSO® plus ORPATHYS® or placebo, and HUTCHMED plans to share the data with regulatory authorities in China to support first-line use.

Filing Explained

Positive Phase III results support possible first-line use, but follow-up and regulatory review remain before any disclosed expansion of China approval.

As a Form 6-K, the report furnishes material home-market information and reports high-level positive results from the Phase III SANOVO trial of ORPATHYS® plus TAGRISSO® in treatment-naïve patients.

The trial is still being followed for its results, and the data will be presented at a forthcoming medical meeting. The filing identifies the combination’s existing China approval as covering patients whose disease progressed after EGFR-TKI therapy, while first-line use is described as a development and regulatory objective rather than an announced approval expansion.

The named checkpoints are continued follow-up, presentation of the data at a medical meeting, and sharing the results with regulatory authorities to support possible first-line use in China.

Key Figures

SANOVO patients randomized: 326 patients TAGRISSO dose: 80 mg once daily ORPATHYS dose: 300/200 mg twice daily +5 more

8 metrics

SANOVO patients randomized 326 patients Treatment-naïve locally advanced or metastatic NSCLC with EGFR mutations and MET overexpression in China

TAGRISSO dose 80 mg once daily Dose in SANOVO trial for all randomized patients

ORPATHYS dose 300/200 mg twice daily Dose in SANOVO based on body weight, combined with TAGRISSO

Proportion of lung cancer deaths 23% Lung cancer share of global cancer deaths cited from WHO

NSCLC share of lung cancers 80-85% Proportion of lung cancer cases diagnosed as NSCLC

EGFR-mutated NSCLC in US/Europe 10-15% Estimated proportion of NSCLC patients with EGFR mutations

EGFR-mutated NSCLC in Asia 30-40% Estimated proportion of NSCLC patients with EGFR mutations in Asia

Advanced disease at NSCLC diagnosis 75% Approximate proportion of NSCLC patients diagnosed with advanced disease

Key Terms

progression-free survival, overall survival, MET overexpression, intention-to-treat, +2 more

6 terms

progression-free survival medical

"demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

overall survival medical

"the combination also demonstrated a very encouraging clinical benefit in overall survival"

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

MET overexpression medical

"patients with MET-Overexpressing EGFR-mutated Lung Cancer in China"

intention-to-treat medical

"in both the high MET and intention-to-treat (“ITT”) patient populations"

A method for analyzing clinical trial results that counts every participant in the group they were originally assigned to, regardless of whether they completed the treatment or followed the protocol. Like judging a sports team's season based on the original roster rather than only the players who actually played every game, it gives a conservative, real-world estimate of how a treatment performs and helps investors judge the likelihood regulators and markets will value the therapy.

tyrosine kinase inhibitor medical

"after disease progression on EGFR-tyrosine kinase inhibitor (“TKI”) therapy"

A tyrosine kinase inhibitor is a type of drug that blocks specific proteins in cells that act like on/off switches for growth and survival signals, often used to stop cancer cells from multiplying. For investors, these drugs matter because their clinical trial results, regulatory approvals, safety profiles, and patent status drive sales potential and company valuation—think of them as precision tools whose effectiveness and market exclusivity determine commercial success.

inside information regulatory

"INSIDE INFORMATION HUTCHMED Announces SANOVO Trial Demonstrated"

Information not available to the public that, if known, would likely cause a company’s stock or bonds to rise or fall—for example, undisclosed earnings, deals, product results, or management plans. It matters because trading on that information gives an unfair advantage, can distort market prices, and is typically illegal or subject to strict rules, so investors watch for proper disclosure and compliance to protect fair, transparent markets.

FAQ

What did HUTCHMED (HCM) announce about the SANOVO Phase III trial?

HUTCHMED announced that the China Phase III SANOVO trial in treatment-naïve EGFR-mutated, MET-overexpressing NSCLC showed a statistically significant and highly clinically meaningful improvement in progression-free survival for ORPATHYS® plus TAGRISSO® versus TAGRISSO® alone, with encouraging overall survival data and no new safety findings.

Which patient population was studied in HUTCHMED’s (HCM) SANOVO trial?

SANOVO enrolled previously untreated patients in China with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations (exon 19 deletion or L858R) and MET overexpression, evaluating ORPATHYS® plus TAGRISSO® versus TAGRISSO® alone as first-line therapy.

What were the primary and key secondary endpoints in HCM’s SANOVO study?

The primary endpoint of SANOVO was progression-free survival (PFS) assessed by investigators. Other endpoints include PFS by independent review, overall survival (OS), objective response rate, duration of response, disease control rate, time to response, and safety, all in treatment-naïve EGFR-mutated, MET-overexpressing NSCLC.

How many patients were enrolled in HUTCHMED’s (HCM) SANOVO trial and how were they treated?

SANOVO randomized 326 treatment-naïve patients in a 1:1 ratio to receive TAGRISSO® 80 mg once daily plus either ORPATHYS® or placebo at 300/200 mg twice daily, with ORPATHYS® dosing based on body weight, to compare the combination against TAGRISSO® alone.

What is the current approval status of ORPATHYS® in China mentioned by HCM?

ORPATHYS® is approved in China for MET exon 14 skipping NSCLC and conditionally approved for MET-amplified gastric or gastroesophageal junction cancer after at least two prior systemic treatments. In combination with TAGRISSO®, it is approved for EGFR mutation-positive NSCLC with MET amplification after EGFR TKI progression.

How common is EGFR-mutated NSCLC according to HUTCHMED’s (HCM) disclosure?

HUTCHMED cites sources indicating that 10–15% of NSCLC patients in the US and Europe, and 30–40% of patients in Asia, have EGFR-mutated NSCLC. Lung cancer accounts for about 23% of global cancer deaths, and 80–85% of lung cancers are NSCLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/31/2026 - 06:58 AM Accepted by SEC EDGAR 08/31/2026 - 06:03 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the Month of August 2026

Commission File Number: 001-37710

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

HUTCHMED (CHINA) LIMITED

Form 6-K

EXHIBIT INDEX


Exhibit No.		Description

Exhibit 99.1		Announcement relating to SANOVO trial demonstrated significant progression-free survival benefit of ORPATHYS^® plus TAGRISSO^® in treatment-naïve patients with MET-overexpressing EGFR-mutated lung cancer in China

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	HUTCHMED (CHINA) LIMITED


	By:	/s/ Johnny Cheng
	Name:	Johnny Cheng
	Title:	Chief Financial Officer

Date: August 31, 2026

Exhibit 99.1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HUTCHMED (China) Limited
和黃醫藥（中國）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 13)

INSIDE INFORMATION

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS^® Plus TAGRISSO^® in Treatment-Naïve Patients with

MET-Overexpressing EGFR-mutated Lung Cancer in China

— Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting —

This announcement is made by HUTCHMED (China) Limited (“HUTCHMED”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Іnside Іnformation Provisions under Part XІVA of the Securities and Futures Ordinance (Cap. 571).

HUTCHMED today announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) whose tumors harbor epidermal growth factor receptor (“EGFR”) mutation and MET overexpression. ORPATHYS^® (savolitinib) plus TAGRISSO^® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (“PFS”) versus TAGRISSO^® alone in both the high MET and intention-to-treat (“ITT”) patient populations.

In both patient populations, the combination also demonstrated a very encouraging clinical benefit in overall survival (“OS”), a secondary endpoint of the trial. The trial will continue to follow-up on these results. These data will be presented at a forthcoming medical meeting.

Professor Yi-Long Wu of the Guangdong Provincial People's Hospital, and the leading Principal Investigator of the SANOVO trial, said: “Co-occurring MET overexpression in treatment-naïve EGFR-mutated NSCLC often compromises the long-term durability of EGFR-TKI monotherapy. The positive findings from SANOVO demonstrate that addressing both pathways upfront with an all-oral, biomarker-directed regimen offers a powerful new approach for these patients whose tumors have MET overexpression. By combining ORPATHYS^® with TAGRISSO^®, we have observed a clear clinical benefit that could reshape primary treatment strategy for this distinct patient population.”

Dr Weiguo Su, Chief Executive Officer¹and Chief Scientific Officer of HUTCHMED, said: “We are thrilled by the positive results from SANOVO, which validate our strategy of addressing MET-driven disease across multiple stages of lung cancer. Building on the strong foundations of our Phase III SAFFRON global study and SACHI study in China in pre-treated patients, SANOVO data further validate the therapeutic strength and versatility of the ORPATHYS^® and TAGRISSO^® combination in first-line patients. We are deeply grateful to all patients and investigators who participated in the trial, and we look forward to sharing the data with regulatory authorities to bring this innovative all-oral combination to the first-line setting in China.”

_____________________________

¹ currently on leave of absence.

Dr Jing He, Head of R&D China, AstraZeneca, said: “These positive data underscore the pivotal role of ORPATHYS^® in intercepting MET-driven resistance early in the treatment journey. By combining the targeted precision of ORPATHYS^® with backbone TAGRISSO^®, SANOVO demonstrates a meaningful clinical advancement for treatment-naïve patients with MET overexpression and EGFR mutation. Together with HUTCHMED, we are excited to advance ORPATHYS^® in China as a transformative, biomarker-directed addition to frontline lung cancer care.”

The safety profile for ORPATHYS^® plus TAGRISSO^® was consistent with the known profiles of each medicine, and there were no new safety findings.

ORPATHYS® plus TAGRISSO^® is approved in China for patients with locally advanced or metastatic EGFR-mutated (“EGFRm”) NSCLC with MET amplification after disease progression on EGFR-tyrosine kinase inhibitor (“TKI”) therapy based on the SACHI Phase III trial. The combination also reported positive high-level results in the SAFFRON global Phase III trial in EGFRm NSCLC with MET overexpression or amplification after disease progression on TAGRISSO^® in August 2026, demonstrating a statistically significant and clinically meaningful improvement in both PFS and overall survival (“OS”).

ORPATHYS^® is being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.

About NSCLC and MET aberrations

Lung cancer is the leading cause of death by cancer globally, accounting for almost one in four (23%) cancer deaths.¹ Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% of patients diagnosed with NSCLC.² Approximately 75% of NSCLC patients are diagnosed with advanced disease.³ Additionally, about 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia, have EGFRm NSCLC.^4,5,6

MET is a tyrosine kinase receptor that has an essential role in normal cell development.⁷ MET overexpression or amplification can lead to tumor growth and the metastatic progression of cancer cells.^7,8

About SANOVO

SANOVO is a blinded, randomized, controlled Phase III study in previously untreated patients with locally advanced or metastatic NSCLC with activating EGFR mutations and MET overexpression in China. The study evaluates the efficacy and safety of ORPATHYS^® in combination with TAGRISSO^® comparing to TAGRISSO^® alone, a standard-of-care treatment option for these patients. A total of 326 treatment-naïve patients with locally advanced or metastatic NSCLC harboring EGFR mutations (exon 19 deletion or L858R) and MET overexpression were randomized in a 1:1 ratio to receive TAGRISSO^® 80 mg once daily plus either ORPATHYS^® or placebo at 300/200 mg twice daily (dosed based on body weight).

The primary endpoint of the study is PFS as assessed by investigators. Other endpoints include PFS assessed by an independent review committee, OS, objective response rate (ORR), duration of response (DoR), disease control rate (DCR), time to response (TTR), and safety. Additional details may be found at clinicaltrials.gov, using identifier NCT05009836.

About ORPATHYS^®

ORPATHYS^® (savolitinib) is an oral, potent and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.

ORPATHYS^® is approved in China for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. ORPATHYS^® also received a conditional approval in China for the treatment of patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. ORPATHYS^® in combination with TAGRISSO^® is approved in China for patients with locally advanced or metastatic EGFR mutation-positive non-squamous NSCLC with MET amplification after disease progression on EGFR TKI therapy based on the SACHI Phase III trial. The combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced or metastatic EGFRm NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment with TAGRISSO^®. This was based on results from the global SAVANNAH Phase II trial. The global, randomized, SAFFRON Phase III trial in the same treatment setting comparing the combination with platinum-based chemotherapy, reported positive high-level results demonstrating a statistically significant and clinically meaningful improvement in PFS and OS in August 2026.

About TAGRISSO^®

TAGRISSO^® (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including the treatment of central nervous system metastases.

TAGRISSO^® is approved as monotherapy in more than 120 countries including the US, EU, China and Japan. Approved indications include for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC, locally advanced or metastatic EGFR T790M mutation-positive NSCLC, adjuvant treatment of early-stage EGFRm NSCLC and locally advanced, unresectable NSCLC following platinum-based chemoradiation therapy. TAGRISSO^® is also approved in combination with chemotherapy in more than 80 countries, including the US, EU, China and Japan, for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of ORPATHYS^®, the further clinical development for ORPATHYS^®, its expectations as to whether any studies on ORPATHYS^®would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of ORPATHYS^®, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of ORPATHYS^®for a targeted indication; the sufficiency of funding; and AstraZeneca’s ability to successfully develop and commercialize ORPATHYS^®. In addition, as certain studies rely on the use of other drug products such as TAGRISSO^®as combination therapeutics with ORPATHYS^®, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

Inside Information

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (as it forms part of retained EU law as defined in the European Union (Withdrawal) Act 2018).

Medical Information

This announcement contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

_________________________________

¹ World Health Organization. International Agency for Research on Cancer. Lung Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf. Accessed August 2026.

² American Cancer Society. What Is Lung Cancer? Available at: https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. Accessed August 2026.

³Chen HJ, et al. Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI. Medicine. 2021;100(6):e24688.

⁴ Szumera-Ciećkiewicz A, et al. EGFR Mutation Testing on Cytological and Histological Samples in Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2013;6:2800-2812.

⁵ Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First- Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011;29:2121-2127.

⁶ Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. J Clin Pathol. 2013;66:79-89.

⁷Uchikawa E, et al. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(4074).

⁸ Wang Q, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;63.

By Order of the Board

Edith Shih

Non-executive Director and Company Secretary

Hong Kong, August 31, 2026

As at the date of this announcement, the Directors of the Company are:

Senior and Lead Independent Non-executive Director)

Chairman and Non-executive Director:

Dr Dan ELDAR

Executive Directors:

Dr Weiguo SU

(Chief Executive Officer and Chief Scientific Officer)

Mr CHENG Chig Fung, Johnny

(Acting Chief Executive Officer and Chief Financial Officer)

Non-executive Directors:

Ms Edith SHIH

Ms Ling YANG

Independent Non-executive Directors:

Dr Renu BHATIA

(Senior and Lead Independent Non-executive Director)

Dr Chaohong HU

Professor TAN Shao Weng, Daniel

Mr WONG Tak Wai

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases

EX-99.1 EX-99.1 42.5 KB